

25 August 2025

30 patients enrolled in innovative US-veteran focused mental health trial – Interim results read out pending

Highlights:

- Target recruitment of 30 patients in US Veteran focused mental health trial achieved
- Trial utilises TRI's single-channel algorithm which uses heart rate and heart rate variability to accurately conduct sleep staging and screen for current Major Depressive Episode
- Trial undertaken alongside the Greater Los Angeles Research and Education Foundation (GLAVREF) and Veterans Affairs (VA) Greater Los Angeles Healthcare System
- All 30 patients have now completed an overnight polysomnography sleep study and the Mini International Neuropsychiatric Interview at the West LA VA Medical Center
- Data being reviewed ahead of interim results read out in coming weeks

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the Company') (ASX: TRI) is pleased to report it has achieved target recruitment, having successfully enrolled 30 patients in its clinical trial evaluating the Company's novel single-lead ECG algorithm to screen for current major depressive episodes (cMDE) in veterans with suspected sleep apnoea (refer ASX Announcement 30 May 2025).

The single-channel ECG algorithm utilised in the trial is an extension of TrivarX's lead asset, MEB-001. The algorithm accurately performs sleep staging and detects cMDE in subjects using only heart rate (HR) and heart rate variability (HRV) metrics.

The 30 patients were enrolled at the the West Los Angeles VA Medical Center and have all completed the required overnight polysomnography (PSG) sleep study and the Mini International Neuropsychiatric Interview (MINI) administrated by qualified health professionals.

The Company will now work with Principal Investigator, Dr Jennifer Martin to review all data associated with the patient cohort with the intention of providing interim results in the coming weeks. Top line results from this will provide TrivarX with a greater insight into the algorithm's broader ability to detect cMDE and its commercialisation potential.

Commentary:

Non-executive Chairman, David Trimboli said: *"The clinical trial at the West LA VA Medical Center has received considerable interest from a number of veterans, allowing the Company to achieve its target enrolment target within the expected timeframe of 12 weeks from first patient recruitment."*

"Work is now underway, alongside Dr Martin and broader Veterans Affairs personnel to review the data generated from the trial prior to an interim analysis being provided to the market in the coming weeks. These results will provide a solid insight into the algorithm's sensitivity and specificity, which are critical for any further commercialisation objectives."

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

ASX ANNOUNCEMENT



Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au